Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Molecular Biology

• Publication date

  2001-04-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/JMBI.2001.4574PMID 11292349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of a pepscan approach to identify epitopes recognised by anti-hTSH monoclonal antibodies.

  1999cited by this paper
• Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1.

  1999cited by this paper
• Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.

  1999cited by this paper
• Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human Antibodies

  1997cited by this paper
• Preventing merozoite invasion of erythrocytes.

  1996cited by this paper
• RASMOL: biomolecular graphics for all.

  1995cited by this paper
• Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein

  1994cited by this paper
• Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein.

  1994cited by this paper
• Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1.

  1993cited by this paper
• High resolution functional analysis of antibody-antigen interactions.

  1992cited by this paper
• Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors.

  1991cited by this paper
• Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

  1991cited by this paper
• Site-specific mutagenesis using asymmetric polymerase chain reaction and a single mutant primer.

  1990cited by this paper
• A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion- inhibiting antibodies

  1990cited by this paper
• Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

  1988cited by this paper
• Three-dimensional structure of an antibody-antigen complex.

  1987cited by this paper
• Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex.

  1987cited by this paper
• Topography of epitopes on a polymorphic schizont antigen of Plasmodium falciparum determined by the binding of monoclonal antibodies in a two‐site radioimmunoassay

  1987cited by this paper
• Continuous and discontinuous protein antigenic determinants

  1986cited by this paper
• Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution

  1986cited by this paper
• Characterization with monoclonal antibodies of a surface antigen of Plasmodium falciparum merozoites.

  1985cited by this paper
• Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites

  1985cited by this paper
• Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

  1984cited by this paper
• Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody

  1982cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Erythrocyte binding peptides: a story in the search for a malaria vaccine

  2025cites this paper
• An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity

  2024cites this paper
• Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate

  2023cites this paper
• Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion

  2022cites this paper
• Transdermal Immunization of Elastic Liposome-Laden Recombinant Chimeric Fusion Protein of P. falciparum (PfMSP-Fu24) Mounts Protective Immune Response

  2021cites this paper
• Orientation of Antigen Display on Self-Assembling Protein Nanoparticles Influences Immunogenicity

  2021cites this paper
• ITEM-THREE analysis of a monoclonal anti-malaria antibody reveals its assembled epitope on the pfMSP119 antigen

  2020cites this paper
• Differences in Anti Malarial Antibody Concentrations and Specificities between Male and Female Ugandan Children

  2020cites this paper
• MSP3 and GLURP with protection from clinical malaria in Ghanaian children

  2020cites this paper
• Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform

  2020cites this paper
• Role of Opsonophagocytosis in Immune Protection against Malaria

  2020cites this paper
• Nanogram and Nanomolar Active Marine Antiplasmodial Antibiotics

  2020cites this paper
• Inhibition of parasite invasion by monoclonal antibody against epidermal growth factor-like domain of Plasmodium vivax merozoite surface protein 1 paralog

  2019cites this paper
• Nanopatterning protein antigens to refocus the immune response.

  2019cites this paper
• Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria

  2017cites this paper
• Far from the Madding Crowd: the Molecular Basis for Immunological Escape of Plasmodium falciparum.

  2017cites this paper
• Control of malaria by bio-therapeutics and drug delivery systems

  2017cites this paper
• Plasmodium falciparum infection and age influence parasite growth inhibition mediated by IgG in Beninese infants.

  2016cites this paper
• Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1

  2016cites this paper
• Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria

  2016cites this paper
• Cloning and Sequence Analysis of Recombinant Plasmodium vivax Merozoite Surface Protein 1 (PvMSP-142 kDa) In pTZ57R/T Vector

  2015cites this paper
• Workshop report: Malaria vaccine development in Europe--preparing for the future.

  2015cites this paper
• Current efforts and future prospects in the development of live mycobacteria as vaccines

  2015cites this paper
• The structure of Plasmodium yoelii merozoite surface protein 119, antibody specificity and implications for malaria vaccine design

  2014cites this paper
• A Novel Malaria Vaccine Candidate Antigen Expressed in Tetrahymena thermophila

  2014cites this paper
• design , antibody specificity and implications for malaria vaccine 19 1 merozoite surface protein Plasmodium yoelii The structure of

  2014cites this paper
• Sequence analysis of Ancylostoma secreted protein 2 ofNecator americanus from Thai isolates

  2013cites this paper
• Immune mechanisms in malaria: new insights in vaccine development

  2013cites this paper
• This information is current as Inhibition of Parasite Growth In Vitro Immunogenicity, and Antibody-Mediated Antigens Enhances Product Yield, Fusion of Two Malaria Vaccine Candidate

  2013cites this paper
• A Chimeric Plasmodium falciparum Merozoite Surface Protein Vaccine Induces High Titers of Parasite Growth Inhibitory Antibodies

  2013cites this paper
• Four promising antigens, BgP32, BgP45, BgP47, and BgP50, for serodiagnosis of Babesia gibsoni infection were classified as B. gibsoni merozoite surface protein family.

  2012cites this paper
• High Affinity Antibodies to Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Malaria

  2012cites this paper
• The Impact of Immune Responses on the Asexual Erythrocytic Stages of Plasmodium and the Implication for Vaccine Development

  2012cites this paper
• Plasmodium falciparum Line-Dependent Association of In Vitro Growth-Inhibitory Activity and Risk of Malaria

  2012cites this paper
• Construction de la réponse anticorps spécifique du paludisme chez le jeune enfant : étude combinée de l’hôte, du parasite et de leur environnement

  2012cites this paper
• Histidine affinity tags affect MSP142 structural stability and immunodominance in mice

  2012cites this paper
• Associations between Antibodies to a Panel of Plasmodium falciparum Specific Antigens and Response to Sub-Optimal Antimalarial Therapy in Kampala, Uganda

  2012influential citation
• Correction: Juxtamembrane Shedding of Plasmodium falciparum AMA1 Is Sequence Independent and Essential, and Helps Evade Invasion-Inhibitory Antibodies

  2012cites this paper
• Plasmodium falciparum 19-Kilodalton Merozoite Surface Protein 1 (MSP1)-Specific Antibodies That Interfere with Parasite Growth In Vitro Can Inhibit MSP1 Processing, Merozoite Invasion, and Intracellular Parasite Development

  2011cites this paper
• Immune responses elicited by co‐immunization of Plasmodium vivax and P. falciparum MSP‐1 using prime‐boost immunization strategies

  2011cites this paper
• An engineered Plasmodium falciparum C‐terminal 19‐kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon‐gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed to malaria

  2011cites this paper
• Enhancing the efficacy of viral vector blood-stage malaria vaccines

  2011influential citation
• Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.

  2011cites this paper
• Juxtamembrane Shedding of Plasmodium falciparum AMA1 Is Sequence Independent and Essential, and Helps Evade Invasion-Inhibitory Antibodies

  2011cites this paper
• Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-119) antigen of Plasmodium falciparum

  2011influential citation
• Atomic fidelity of subunit-based chemically-synthesized antimalarial vaccine components.

  2010cites this paper
• Total immunoglobulin G and IgG1 subclass levels specific for the MSP-1(19) of Plasmodium falciparum are different in individuals with either processing-inhibitory, blocking or neutral antibodies.

  2010cites this paper
• Epitope mapping of PfCP-2.9, an asexual blood-stage vaccine candidate of Plasmodium falciparum

  2010influential citation
• Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum Merozoite Surface Protein 1 types in individuals in Nigeria with sub-microscopic infection

  2010cites this paper
• Malaria vaccine development based on merozoite surface proteins of Plasmodium falciparum

  2010cites this paper
• Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria

  2010cites this paper
• Open Access RESEARCH

  2010cites this paper
• blood-stage vaccine candidate of Plasmodium falciparum

  2010cites this paper
• Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion

  2010cites this paper
• Plasmodium falciparum 19 kDa of merozoite surface protein-1 (MSP-1(19)) expressed in Mycobacterium bovis bacille Calmette Guerin (BCG) is reactive with an inhibitory but not a blocking monoclonal antibody.

  2010influential citation
• Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends

  2010cites this paper
• Development in malarial vaccine: A review.

  2010cites this paper
• The future for blood‐stage vaccines against malaria

  2009cites this paper
• Fc‐receptors and immunity to malaria: from models to vaccines

  2009cites this paper
• MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum

  2009cites this paper
• Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection

  2009cites this paper
• ntibody specificities of children living in a malaria endemic area to inhibitory nd blocking epitopes on MSP-119 of Plasmodium falciparum

  2009influential citation
• Inhibition of Erythrocyte Invasion and Plasmodium falciparum Merozoite Surface Protein 1 Processing by Human Immunoglobulin G1 (IgG1) and IgG3 Antibodies

  2009cites this paper
• IgG subclasses pattern and high-avidity antibody to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in an unstable hypoendemic region in Iran.

  2009cites this paper
• Structure of a Fab Complex with the C-terminal fragment of merozoite surface protein-1 of Plasmodium vivax determined by Computational Docking

  2009cites this paper
• Chapter 65 – Malaria

  2009cites this paper
• Antibody specificities of children living in a malaria endemic area to inhibitory and blocking epitopes on MSP-1 19 of Plasmodium falciparum.

  2009cites this paper
• Plasmodium falciparum Merozoite Surface Protein 1 (MSP-1)-MSP-3 Chimeric Protein: Immunogenicity Determined with Human-Compatible Adjuvants and Induction of Protective Immune Response

  2009influential citation
• The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria

  2009cites this paper
• Modification of a human monoclonal antibody Fab fragment specific for Plasmodium falciparum 19-kDa C-terminal merozoite surface protein 1 by site-directed mutagenesis

  2008cites this paper
• Evaluation Of The Efficacy Of Chloroplast-derived Antigensagainst Malaria

  2008cites this paper
• Malaria vaccines: immunity, models and monoclonal antibodies.

  2008cites this paper
• Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacy against Plasmodium chabaudi malaria based on prechallenge antibody responses Running title: Correlates of AMA1 and MSP1 vaccine-induced immunity

  2008cites this paper
• Protection Induced by Plasmodium falciparum MSP142 Is Strain-Specific, Antigen and Adjuvant Dependent, and Correlates with Antibody Responses

  2008cites this paper
• Comparative Testing of Six Antigen-Based Malaria Vaccine Candidates Directed Toward Merozoite-Stage Plasmodium falciparum

  2008cites this paper
• Prediction of Merozoite Surface Protein 1 and Apical Membrane Antigen 1 Vaccine Efficacies against Plasmodium chabaudi Malaria Based on Prechallenge Antibody Responses

  2008cites this paper
• Immune responses to polymorphic antigens and protection against severe malaria in Kenyan children

  2008cites this paper
• Surface Plasmon Resonance Imaging Measurements of Biomolecular Arrays

  2008cites this paper
• Identifying merozoite surface protein 4 and merozoite surface protein 7 Plasmodium falciparum protein family members specifically binding to human erythrocytes suggests a new malarial parasite-redundant survival mechanism.

  2007cites this paper
• Epidemiological factors that promote the development of severe malaria anaemia in children in Ibadan.

  2007cites this paper
• Malaria Vaccine-Related Benefits of a Single Protein Comprising Plasmodium falciparum Apical Membrane Antigen 1 Domains I and II Fused to a Modified Form of the 19-Kilodalton C-Terminal Fragment of Merozoite Surface Protein 1

  2007cites this paper
• The Importance of Human FcγRI in Mediating Protection to Malaria

  2007cites this paper
• Structural studies on Plasmodium vivax merozoite surface protein-1.

  2007cites this paper
• Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

  2007cites this paper
• Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.

  2007cites this paper
• Production of High-Affinity Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 of Plasmodium falciparum

  2007cites this paper
• Vaccines for malaria - : prospects and promise

  2007cites this paper
• The stevor multigene family of Plasmodium falciparum

  2007cites this paper
• Interaction of malaria parasite‐inhibitory antibodies with the merozoite surface protein MSP119 by computational docking

  2006cites this paper
• Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.

  2006cites this paper
• Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.

  2006cites this paper
• Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes

  2006cites this paper
• Variable surface molecules of the plasmodium falciparum infected erythrocyte and merozoite

  2006cites this paper
• Functional and immunological insights from the three-dimensional structures of Plasmodium surface proteins.

  2006cites this paper
• Immunoglobulin G Antibodies to Merozoite Surface Antigens Are Associated with Recovery from Chloroquine-Resistant Plasmodium falciparum in Gambian Children

  2006cites this paper
• Preclinical Evaluation of a Chimeric Malaria Vaccine Candidate in Montanide ISA 720®: Immunogenecity and Safety in Rhesus Macaques

  2006cites this paper
• Analysis of Antibodies Directed against Merozoite Surface Protein 1 of the Human Malaria Parasite Plasmodium falciparum

  2006cites this paper
• Hydrophobic moeties in recombinant proteins are crucial to generate efficient saponin-based vaccine against Apicomplexan Babesia divergens.

  2006cites this paper
• Synthesis, Solution Structure and Immune Recognition of an Epidermal Growth Factor‐Like Domain from Plasmodium falciparum Merozoite Surface Protein‐1

  2006cites this paper
• Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag.

  2006cites this paper